LungLife AI, INC Block Listing Application (8564R)

TIDMLLAI

RNS Number : 8564R

LungLife AI, INC

10 November 2021

LungLife AI, Inc.

("LungLife" or the "Company")

Block Listing Application

LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the "Block Admission") has been made to the London Stock Exchange for up to 1,356,139 common shares of US $0.0001 each (the "Block Listing Shares") to be admitted to trading on AIM ("Admission").

The common shares that are being reserved under this block listing application will be issued by the Company, as required, in order to satisfy the exercise of share options and vested awards pursuant to the terms of the following share plans (the "Schemes"):

 
 Scheme                              No. of common shares under 
                                      block listing application 
 2010 Stock Incentive Plan                              480,775 
                                    --------------------------- 
 2020 Stock Incentive Plan                              201,374 
                                    --------------------------- 
 2021 Omnibus Long-Term Incentive 
  Plan                                                  673,990 
                                    ---------------------------

The Block Listing Shares will, upon issue, rank equally with all other common shares of US $0.0001 each in the capital of the Company that are then in issue. The Block Listing Admission is expected to become effective on 15 November 2021.

For further information please contact:

 
LungLife AI, Inc.                                                           www.lunglifeai.com 
Paul Pagano, CEO                                                               Via Walbrook PR 
David Anderson, CFO 
 
Investec Bank plc (Nominated Adviser                                  Tel: +44 (0)20 7597 5970 
 & Broker) 
Daniel Adams / Virginia Bull / Cameron 
 MacRitchie 
 
Walbrook PR Limited                      Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com 
Paul McManus / Alice Woodings                               Mob: 07980 541 893 / 07407 804 654

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSFSLFWUEFSEFF

(END) Dow Jones Newswires

November 10, 2021 02:00 ET (07:00 GMT)

Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024